MediWound (NASDAQ:MDWD) Upgraded at Wall Street Zen
Wall Street Zen upgraded MediWound (NASDAQ:MDWD) from a "sell" to "hold" rating. Other analysts have varied opinions, with some maintaining a "sell" and others a "buy" rating. The stock has a "Moderate Buy" consensus with a target price of $33.50. MediWound's recent earnings beat expectations, and institutional investors have increased their positions in the company. Despite the "Moderate Buy" rating, top analysts suggest better investment options than MediWound.
MediWound (NASDAQ:MDWD - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.
Several other equities analysts have also issued reports on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of MediWound in a research note on Wednesday, October 8th. Zacks Research upgraded shares of MediWound from a "strong sell" rating to a "hold" rating in a research report on Tuesday, November 11th. Finally, HC Wainwright reissued a "buy" rating and set a $36.00 target price (up from $31.00) on shares of MediWound in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $33.50.
View Our Latest Report on MediWound
MediWound Trading Up 1.2%
Shares of MediWound stock opened at $17.06 on Friday. The business has a 50-day moving average price of $18.02 and a two-hundred day moving average price of $18.83. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50. The company has a market cap of $189.14 million, a P/E ratio of -6.46 and a beta of 0.22.
MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings data on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.57. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.The company had revenue of $5.43 million for the quarter, compared to the consensus estimate of $6.56 million. Equities research analysts forecast that MediWound will post -2.66 EPS for the current fiscal year.
Institutional Trading of MediWound
Institutional investors have recently made changes to their positions in the company. Rosalind Advisors Inc. lifted its position in shares of MediWound by 84.0% during the third quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company's stock valued at $13,498,000 after purchasing an additional 341,993 shares in the last quarter. Meitav Investment House Ltd. increased its stake in MediWound by 825.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company's stock valued at $5,241,000 after buying an additional 260,116 shares during the last quarter. Millennium Management LLC lifted its position in shares of MediWound by 355.6% during the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company's stock worth $3,160,000 after buying an additional 136,884 shares in the last quarter. Menora Mivtachim Holdings LTD. boosted its stake in shares of MediWound by 348.8% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company's stock worth $1,415,000 after buying an additional 61,039 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new position in shares of MediWound in the 3rd quarter worth approximately $1,042,000. Institutional investors own 46.83% of the company's stock.
MediWound Company Profile
(Get Free Report)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
See Also
- Five stocks we like better than MediWound
- Consumer Staples Stocks, Explained
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- What is the Australian Securities Exchange (ASX)
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in MediWound Right Now?
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
